BIO-TECHNE Corp (TECH) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 264.71M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $264.71M | (m) | (m) |
| 2026-03-31 | (m) | (m) | $209.82M | (m) | (m) |
| 2025-12-31 | (m) | (m) | $172.88M | (m) | (m) |
| 2025-09-30 | (m) | (m) | $144.96M | (m) | (m) |
| 2025-06-30 | (m) | (m) | $162.19M | (m) | (m) |
| 2025-03-31 | (m) | (m) | $140.67M | (m) | (m) |
| 2024-12-31 | (m) | (m) | $177.55M | (m) | (m) |
| 2024-09-30 | (m) | (m) | $187.54M | (m) | (m) |
| 2024-06-30 | (m) | (m) | $151.79M | (m) | (m) |
| 2024-03-31 | (m) | (m) | $139.91M | (m) | (m) |
| 2023-12-31 | (m) | (m) | $130.13M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $148.66M | (m) | (m) |
| 2023-06-30 | (m) | (m) | $180.57M | (m) | (m) |
| 2023-03-31 | (m) | (m) | $127.28M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $164.68M | (m) | (m) |
| 2022-09-30 | (m) | (m) | $165.26M | (m) | (m) |
| 2022-06-30 | $247.03M | (m) | $172.57M | $74.46M | (m) |
| 2022-03-31 | $231.17M | (m) | $160.82M | $70.35M | (m) |
| 2021-12-31 | $278.98M | (m) | $211.84M | $67.14M | (m) |
| 2021-09-30 | $235.06M | (m) | $196.32M | $38.74M | (m) |
| 2021-06-30 | $231.55M | (m) | $199.09M | $32.46M | (m) |
| 2021-03-31 | $276.24M | (m) | $186.14M | $90.11M | (m) |
| 2020-12-31 | $282.95M | (m) | $165.53M | $117.43M | (m) |
| 2020-09-30 | $287.39M | (m) | $169.40M | $117.99M | (m) |
| 2020-06-30 | $270.89M | (m) | $146.63M | $124.27M | (m) |
| 2020-03-31 | $261.09M | (m) | $156.22M | $104.87M | (m) |
| 2019-12-31 | $243.95M | (m) | $110.29M | $133.66M | (m) |
| 2019-09-30 | $158.41M | (m) | $99.89M | $58.52M | (m) |
| 2019-06-30 | $166.03M | (m) | $100.89M | $65.15M | (m) |
| 2019-03-31 | $178.79M | (m) | $95.56M | $83.23M | (m) |
| 2018-12-31 | $156.53M | (m) | $85.89M | $70.65M | (m) |
| 2018-09-30 | $163.72M | (m) | $94.67M | $69.05M | (m) |
| 2018-06-30 | $181.75M | (m) | $121.99M | $59.76M | (m) |
| 2018-03-31 | $176.43M | (m) | $86.61M | $89.83M | (m) |
| 2017-12-31 | $162.38M | (m) | $121.46M | $40.93M | (m) |
| 2017-09-30 | $122.72M | (m) | $72.46M | $50.26M | (m) |
| 2017-06-30 | $157.71M | (m) | $91.61M | $66.10M | (m) |
| 2017-03-31 | $113.62M | (m) | $59.84M | $53.78M | (m) |
| 2016-12-31 | $115.50M | (m) | $58.94M | $56.56M | (m) |
| 2016-09-30 | $121.97M | (m) | $69.59M | $52.38M | (m) |
| 2016-06-30 | $95.83M | (m) | $64.24M | $31.60M | (m) |
| 2016-03-31 | $84.59M | (m) | $65.71M | $18.87M | (m) |
| 2015-12-31 | $113.92M | (m) | $62.45M | $51.47M | (m) |
| 2015-09-30 | $87.27M | (m) | $48.84M | $38.42M | (m) |
| 2015-06-30 | $110.92M | (m) | $54.53M | $56.39M | (m) |
| 2015-03-31 | $159.95M | (m) | $106.45M | $53.50M | (m) |
| 2014-12-31 | $139.94M | (m) | $92.97M | $46.97M | (m) |
| 2014-09-30 | $130.81M | (m) | $98.24M | $32.57M | (m) |
| 2014-06-30 | $363.35M | (m) | $318.57M | $44.79M | (m) |
| 2014-03-31 | $220.13M | (m) | $123.60M | $96.53M | (m) |
| 2013-12-31 | $186.86M | (m) | $98.40M | $88.45M | (m) |
| 2013-09-30 | $184.70M | (m) | $83.86M | $100.84M | (m) |
| 2013-06-30 | $332.94M | (m) | $163.79M | $169.15M | (m) |
| 2013-03-31 | $312.88M | (m) | $150.71M | $162.16M | (m) |
| 2012-12-31 | $286.10M | (m) | $143.29M | $142.81M | (m) |
| 2012-09-30 | $273.07M | (m) | $130.81M | $142.26M | (m) |
| 2012-06-30 | $268.99M | (m) | $116.67M | $152.31M | (m) |
| 2012-03-31 | $219.60M | (m) | $95.28M | $124.33M | (m) |
| 2011-12-31 | $137.75M | (m) | $80.99M | $56.76M | (m) |
| 2011-09-30 | $133.35M | (m) | $79.23M | $54.12M | (m) |
| 2011-06-30 | $140.81M | (m) | $77.61M | $63.20M | (m) |
| 2011-03-31 | $213.90M | (m) | $158.63M | $55.27M | (m) |
| 2010-12-31 | $194.86M | (m) | $135.88M | $58.99M | (m) |
| 2010-09-30 | $172.63M | (m) | $115.01M | $57.62M | (m) |
| 2010-06-30 | $138.81M | (m) | $94.14M | $44.67M | (m) |
| 2010-03-31 | (m) | (m) | $108.24M | (m) | (m) |
| 2009-12-31 | (m) | (m) | $195.55M | (m) | (m) |
| 2009-09-30 | (m) | (m) | $174.76M | (m) | (m) |
| 2009-06-30 | (m) | (m) | $160.94M | (m) | (m) |
| 2008-06-30 | (m) | (m) | $166.99M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |